Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Launches New Pricing Model, Charges Monthly Fee

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Direct-to-consumer genetics testing firm 23andMe has moved to a subscription-based pricing plan that now includes a one year contract and an additional charge of $5 per month.

Along with the change in pricing, the company has done away with its separate Ancestry Edition and Health Edition products, which are now part of one service, called Complete Edition, that the firm offers. The base price for the testing service remains at $499.

The Ancestry and Health Edition products were launched a year ago by 23andMe.

The changes took effect on Nov. 22. After the initial year expires, the contract will go to a month-to-month model, and customers will be able to cancel their contract at any time, a spokeswoman for Mountain View, Calif.-based 23andMe said.

In an e-mail, she said the new monthly charge is based on the company's need to update its test and customers' test results as new genetic discoveries are made. The company's scientific team continually evaluates the latest scientific studies on genetic associations and on average incorporates two to five new genetic discoveries into 23andMe's service each month.

In a separate announcement today, 23andMe said that it has transitioned to the third version of its genotyping array, enabling it to test approximately one million SNPs. Customers who purchase the 23andMe Personal Genome Service today or after will have their DNA tested on the new version of the array, it said. The new chip nearly doubles the number of SNPs for which the firm previously tested.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.